• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

65 岁及以上成年人在初级保健中针对有症状的 SARS-CoV-2 感染的疫苗有效性：I-MOVE-COVID-19 项目，欧洲，2020 年 12 月至 2021 年 5 月。

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.

机构信息

Epiconcept, Paris, France.

Nivel, Utrecht, the Netherlands.

出版信息

Euro Surveill. 2021 Jul;26(29). doi: 10.2807/1560-7917.ES.2021.26.29.2100670.

DOI:10.2807/1560-7917.ES.2021.26.29.2100670
PMID:34296676
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8299744/
Abstract

We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

摘要

我们使用多中心病例对照设计在 8 个欧洲国家的老年人群（≥65 岁）中测量了初级保健/门诊水平的 COVID-19 疫苗对有症状的 SARS-CoV-2 感染的疫苗有效性（VE）。我们在主要分析中纳入了 592 例 SARS-CoV-2 病例和 4372 例阴性对照。一剂疫苗的 VE 为 62%（95%CI：45-74），完全接种疫苗的 VE 为 89%（95%CI：79-94）。COVID-19 疫苗对初级保健/门诊水平的 COVID-19 表现提供了良好的保护，特别是在完全接种疫苗的人群中。

相似文献

1
Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.65 岁及以上成年人在初级保健中针对有症状的 SARS-CoV-2 感染的疫苗有效性：I-MOVE-COVID-19 项目，欧洲，2020 年 12 月至 2021 年 5 月。
Euro Surveill. 2021 Jul;26(29). doi: 10.2807/1560-7917.ES.2021.26.29.2100670.
2
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.2021 年 12 月至 2022 年 6 月，在一项多中心初级保健研究中，针对成年人和青少年的 SARS-CoV-2 BA.1/BA.2 谱系的 COVID-19 疫苗对有症状感染的有效性，欧洲。
Euro Surveill. 2024 Mar;29(13). doi: 10.2807/1560-7917.ES.2024.29.13.2300403.
3
Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021.2021 年 7 月至 8 月，在欧洲主要德尔塔（Delta）传播期间，初级保健和社区层面针对 COVID-19 的完全初级疫苗接种的有效性：多中心分析，I-MOVE-COVID-19 和 ECDC 网络。
Euro Surveill. 2022 May;27(21). doi: 10.2807/1560-7917.ES.2022.27.21.2101104.
4
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.2023 年秋季欧洲开展的 COVID-19 疫苗接种效果：基于 VEBIS 初级保健病例对照研究的结果，2023 年 9 月-2024 年 1 月。
Vaccine. 2024 Jul 25;42(19):3931-3937. doi: 10.1016/j.vaccine.2024.05.067. Epub 2024 Jun 4.
5
Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.接种 BNT162b2 疫苗 13 至 24 天后对 SARS-CoV-2 感染有效性的评估。
JAMA Netw Open. 2021 Jun 1;4(6):e2115985. doi: 10.1001/jamanetworkopen.2021.15985.
6
Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.在广州，灭活的 SARS-CoV-2 疫苗对 Delta 变异株感染的有效性：一项病例对照的真实世界研究。
Emerg Microbes Infect. 2021 Dec;10(1):1751-1759. doi: 10.1080/22221751.2021.1969291.
7
A case control study to assess effectiveness of measles containing vaccines in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children.一项病例对照研究，评估含麻疹疫苗预防儿童严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的效果。
Hum Vaccin Immunother. 2021 Oct 3;17(10):3316-3321. doi: 10.1080/21645515.2021.1930471. Epub 2021 Jun 15.
8
Absence of association between 2019-20 influenza vaccination and COVID-19: Results of the European I-MOVE-COVID-19 primary care project, March-August 2020.2019-20 年流感疫苗接种与 COVID-19 之间不存在关联：2020 年 3 月至 8 月，欧洲 I-MOVE-COVID-19 初级保健项目的结果。
Influenza Other Respir Viruses. 2021 Jul;15(4):429-438. doi: 10.1111/irv.12839. Epub 2021 Jan 22.
9
Prioritizing the First Doses of SARS-CoV-2 Vaccine to Save the Elderly: The Case Study of Italy.优先为老年人接种 SARS-CoV-2 疫苗以拯救老年人：意大利的案例研究。
Front Public Health. 2021 Jul 14;9:684760. doi: 10.3389/fpubh.2021.684760. eCollection 2021.
10
Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021.疫苗接种后，熟练护理机构居民和工作人员中的 SARS-CoV-2 感染 - 伊利诺伊州芝加哥，2020 年 12 月至 2021 年 3 月。
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):632-638. doi: 10.15585/mmwr.mm7017e1.

引用本文的文献

1
Effects of vaccination against COVID-19 on the emotional health of older adults.接种 COVID-19 疫苗对老年人情绪健康的影响。
F1000Res. 2023 May 16;11:868. doi: 10.12688/f1000research.123395.2. eCollection 2022.
2
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.2022 年至 2023 年秋冬期间，老年欧洲人群中的 COVID-19 疫苗有效性。
JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001/jamanetworkopen.2024.19258.
3
Area and individual level analyses of demographic and socio-economic disparities in COVID-19 vaccination uptake in Belgium.比利时新冠疫苗接种中人口统计学和社会经济差异的地区及个体层面分析。
Vaccine X. 2024 May 3;18:100496. doi: 10.1016/j.jvacx.2024.100496. eCollection 2024 Jun.
4
Presenting clinical symptoms of post-COVID-19 breakthrough infection: Predictors of mortality in a Middle Eastern population.新冠病毒感染突破病例的临床症状表现：中东人群的死亡预测因素
Vaccine X. 2024 May 4;18:100495. doi: 10.1016/j.jvacx.2024.100495. eCollection 2024 Jun.
5
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.2021 年 12 月至 2022 年 6 月，在一项多中心初级保健研究中，针对成年人和青少年的 SARS-CoV-2 BA.1/BA.2 谱系的 COVID-19 疫苗对有症状感染的有效性，欧洲。
Euro Surveill. 2024 Mar;29(13). doi: 10.2807/1560-7917.ES.2024.29.13.2300403.
6
Data Resource Profile: Results Analysis Base of Navarre (BARDENA).数据资源简介：纳瓦拉结果分析库（BARDENA）
Int J Epidemiol. 2023 Dec 25;52(6):e301-e307. doi: 10.1093/ije/dyad144.
7
COVID-19 pandemic in prisons in Spain: characteristics of cases and implemented control measures, March 2020-June 2022.西班牙监狱中的 COVID-19 疫情：2020 年 3 月至 2022 年 6 月期间的病例特征和实施的控制措施。
Public Health. 2023 May;218:45-52. doi: 10.1016/j.puhe.2023.02.013. Epub 2023 Feb 22.
8
Relationships Between Social Vulnerability and Coronavirus Disease 2019 Vaccination Coverage and Vaccine Effectiveness.社会脆弱性与 2019 年冠状病毒病疫苗接种覆盖率和疫苗有效性之间的关系。
Clin Infect Dis. 2023 May 3;76(9):1615-1625. doi: 10.1093/cid/ciad003.
9
Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies.辉瑞-BioNTech COVID-19 疫苗的有效性作为政策行动的证据：一项非随机研究的快速系统评价和荟萃分析。
PLoS One. 2022 Dec 6;17(12):e0278624. doi: 10.1371/journal.pone.0278624. eCollection 2022.
10
Real-Time Monitoring of the Effectiveness of Six COVID-19 Vaccines against Laboratory-Confirmed COVID-19 in Hungary in 2021 Using the Screening Method.2021年在匈牙利采用筛查方法对六种新冠疫苗预防实验室确诊新冠病毒感染有效性的实时监测
Vaccines (Basel). 2022 Oct 29;10(11):1824. doi: 10.3390/vaccines10111824.

本文引用的文献

1
Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.新冠病毒疫苗引入后效果评估：世界卫生组织临时指南摘要。
Vaccine. 2021 Jul 5;39(30):4013-4024. doi: 10.1016/j.vaccine.2021.05.099. Epub 2021 Jun 1.
2
Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.接种 BNT162b2 疫苗 13 至 24 天后对 SARS-CoV-2 感染有效性的评估。
JAMA Netw Open. 2021 Jun 1;4(6):e2115985. doi: 10.1001/jamanetworkopen.2021.15985.
3
Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021.2021 年 1 月至 4 月，西班牙纳瓦拉地区 COVID-19 疫苗预防 SARS-CoV-2 感染和住院的有效性。
Euro Surveill. 2021 May;26(21). doi: 10.2807/1560-7917.ES.2021.26.21.2100438.
4
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.辉瑞-生物科技疫苗和牛津-阿斯利康疫苗对英格兰老年人新冠病毒相关症状、住院及死亡率的有效性：检测阴性病例对照研究
BMJ. 2021 May 13;373:n1088. doi: 10.1136/bmj.n1088.
5
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.以色列全国疫苗接种运动后，mRNA BNT162b2疫苗对SARS-CoV-2感染及COVID-19病例、住院和死亡的影响与效果：一项利用国家监测数据的观察性研究
Lancet. 2021 May 15;397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5.
6
Safety of COVID-19 vaccines administered in the EU: Should we be concerned?在欧盟接种的新冠疫苗的安全性：我们应该担心吗？
Toxicol Rep. 2021;8:871-879. doi: 10.1016/j.toxrep.2021.04.003. Epub 2021 Apr 20.
7
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2 mRNA 新冠病毒疫苗在全国大规模疫苗接种环境中的效果。
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
8
Postlicensure Evaluation of COVID-19 Vaccines.新冠疫苗上市后评估
JAMA. 2020 Nov 17;324(19):1939-1940. doi: 10.1001/jama.2020.19328.
9
Basic principles of test-negative design in evaluating influenza vaccine effectiveness.评估流感疫苗效力时检测阴性设计的基本原理。
Vaccine. 2017 Aug 24;35(36):4796-4800. doi: 10.1016/j.vaccine.2017.07.003.
10
The test-negative design for estimating influenza vaccine effectiveness.应用病例对照研究估计流感疫苗效力。
Vaccine. 2013 Apr 19;31(17):2165-8. doi: 10.1016/j.vaccine.2013.02.053. Epub 2013 Mar 13.